Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7589831 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
RO7589831 + pembrolizumab is a combination of two investigational and approved pharmaceutical agents under evaluation for the treatment of advanced solid tumors characterized by microsatellite instability (MSI) and/or deficient mismatch repair (dMMR). RO7589831 is an orally administered, first-in-class small molecule inhibitor of Werner syndrome ATP-dependent helicase (WRN), a protein important for DNA repair in cells. By inhibiting WRN, RO7589831 is intended to block the growth of tumors with MSI and/or dMMR phenotypes. Pembrolizumab, marketed as Keytruda, is an anti–PD-1 monoclonal antibody checkpoint inhibitor that enhances anti-tumor immune responses by preventing the inhibition of T cell activity. The combination aims to synergistically disrupt tumor survival by direct WRN inhibition and augmenting immune-mediated tumor cell killing. This combination is currently in phase I clinical studies for safety, pharmacokinetics, and anti-tumor activity in adults with advanced solid tumors.
- Brand names
- Keytruda
- Other names
- MK-3475MK3475MK 3475
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)WRN (Werner syndrome ATP-dependent helicase)
Beyond the preview
Go deeper on RO7589831 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7589831 + pembrolizumab.